Pan-tumour analysis of COX-2 expression in dogs
Copyright © 2024 Elsevier Ltd. All rights reserved..
Cyclooxgenase-2 (COX-2) is associated with inflammatory microenvironment and tumour progression. COX-2 expression was reported in canine tumours, and anti-COX treatment showed therapeutic effects in selected tumour types. Currently, direct comparisons between different tumour types or reports were impossible due to varying evaluation protocols. Additionally, COX-2 expression in relatively uncommon tumours were yet to be evaluated. Here, we analysed COX-2 expression across various tumour types in dogs in a consistent protocol, aiming to revisit accumulated evidence in the field and report novel candidate tumours for anti-COX therapy. COX-2 expression in 32 histological types of tumours, which consisted of 347 samples in total, was investigated using immunohistochemistry followed by the Belshaw's method scoring (range: 0-12). More than the half of the samples expressed COX-2 in mast cell tumours, transitional cell carcinoma in the urinary tract, squamous cell carcinoma, liposarcoma, and melanoma, with COX-2 median scores ranging from 1-8. On the other hand, <20% tissues expressed COX-2 in the half of tumour types investigated. Overall COX-2 positive rate was 27%. In conclusion, the results confirmed COX-2 expression in the well-known COX-2-expresing tumour types and suggested novel candidate tumours for anti-COX-2 therapy. At the same time, overall COX-2 expression was low, and inter- and intra-histology heterogeneity was apparent. This study will provide a foundation reference for future research in canine tumours.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:304 |
|---|---|
| Enthalten in: |
Veterinary journal (London, England : 1997) - 304(2024) vom: 18. Apr., Seite 106064 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Eto, Shotaro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COX-2 |
|---|
| Anmerkungen: |
Date Completed 16.04.2024 Date Revised 16.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.tvjl.2024.106064 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367327783 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367327783 | ||
| 003 | DE-627 | ||
| 005 | 20240416232450.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240120s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tvjl.2024.106064 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM367327783 | ||
| 035 | |a (NLM)38242282 | ||
| 035 | |a (PII)S1090-0233(24)00003-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Eto, Shotaro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pan-tumour analysis of COX-2 expression in dogs |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.04.2024 | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Cyclooxgenase-2 (COX-2) is associated with inflammatory microenvironment and tumour progression. COX-2 expression was reported in canine tumours, and anti-COX treatment showed therapeutic effects in selected tumour types. Currently, direct comparisons between different tumour types or reports were impossible due to varying evaluation protocols. Additionally, COX-2 expression in relatively uncommon tumours were yet to be evaluated. Here, we analysed COX-2 expression across various tumour types in dogs in a consistent protocol, aiming to revisit accumulated evidence in the field and report novel candidate tumours for anti-COX therapy. COX-2 expression in 32 histological types of tumours, which consisted of 347 samples in total, was investigated using immunohistochemistry followed by the Belshaw's method scoring (range: 0-12). More than the half of the samples expressed COX-2 in mast cell tumours, transitional cell carcinoma in the urinary tract, squamous cell carcinoma, liposarcoma, and melanoma, with COX-2 median scores ranging from 1-8. On the other hand, <20% tissues expressed COX-2 in the half of tumour types investigated. Overall COX-2 positive rate was 27%. In conclusion, the results confirmed COX-2 expression in the well-known COX-2-expresing tumour types and suggested novel candidate tumours for anti-COX-2 therapy. At the same time, overall COX-2 expression was low, and inter- and intra-histology heterogeneity was apparent. This study will provide a foundation reference for future research in canine tumours | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COX-2 | |
| 650 | 4 | |a Canine cancer | |
| 650 | 4 | |a Immunohistochemistry | |
| 650 | 7 | |a Cyclooxygenase 2 |2 NLM | |
| 650 | 7 | |a EC 1.14.99.1 |2 NLM | |
| 700 | 1 | |a Shinada, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Saeki, Kohei |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuboi, Masaya |e verfasserin |4 aut | |
| 700 | 1 | |a Kamoto, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshitake, Ryohei |e verfasserin |4 aut | |
| 700 | 1 | |a Chambers, James |e verfasserin |4 aut | |
| 700 | 1 | |a Uchida, Kazuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Daiki |e verfasserin |4 aut | |
| 700 | 1 | |a Nishimura, Ryohei |e verfasserin |4 aut | |
| 700 | 1 | |a Nakagawa, Takayuki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Veterinary journal (London, England : 1997) |d 1997 |g 304(2024) vom: 18. Apr., Seite 106064 |w (DE-627)NLM090812069 |x 1532-2971 |7 nnns |
| 773 | 1 | 8 | |g volume:304 |g year:2024 |g day:18 |g month:04 |g pages:106064 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tvjl.2024.106064 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 304 |j 2024 |b 18 |c 04 |h 106064 | ||